Acute Leukemia Rakesh Biswas MD, Professor, Department of Medicine, People's College of Medical Sciences, Bhanpur, Bhopal, India.

Slides:



Advertisements
Similar presentations
Non Hodgkin’s lymphoma
Advertisements

TA OGUNLESI (FWACP)1 CHILDHOOD LEUKAEMIA. TA OGUNLESI (FWACP)2 LEUKAEMIA Heterogenous group of malignant disorders Characterised by uncontrolled clonal.
Acute Promyelocytic Leukemia
Aplastic Anemia Rakesh Biswas
Acute leukemia Mohammed Al-matrafi.
HAEMATOLOGY MODULE: LEUKAEMIA (LECTURE 1) CHEMOTHERAPY Adult Medical-Surgical Nursing.
Introduction To Haematological Malignancies
LEUKEMIA.
Chronic leukaemias Chronic myelogenous leukaemia Chronic myelogenous leukaemia Chronic lymphocytic leukaemia Chronic lymphocytic leukaemia.
LEUKEMIA—HEMATOLOGY {S1}
Acute Lymphoblastic Leukemia Maggie Davis Hovda 5/26/2009.
Acute lymphoblastic leukemia (ALL)
Acute Leukaemia Dr. Soheir Adam, MRCPath Assistant Professor Department of Haematology, KAUH.
Acute lymphoblastic leukemia (ALL)
ACUTE MYELOID LEUKEMIA Irit Avivi
Leukemia Maturation of Myeloid Cells Dr. Rania Alhady.
Rakesh Biswas MD Professor, Medicine, People's College of Medical Sciences, Bhopal, India Lecture first conceived and delivered to medicine undergrads.
LEUKEMIAS Dr Mehboob Khan Pathologist
Chapter 17 Chronic Leukemias.
Chronic Leukemia Dr. Rania Alhady Chronic Lymphocytic leukemia (CLL):
Chapter 25: Acute Lymphoblastic Leukemia. Causes a wide spectrum of syndromes – From involvement of bone marrow and peripheral blood(leukemias) to those.
Acute Myeloid Leukemias (AML)
The acute Leukemias are clonal hematopoietic malignant disease that arise from the malignant T r a n s f o r m a t i o n of an early Hematopoietic stem.
Acute Myeloid Leukemia. Case Presentation 33 yo Filipino male presents with back pain, fevers, weight loss, and general malaise 33 yo Filipino male presents.
LIBYAN EXPERIENCE IN PEDIATRIC ACUTE MYELOID LEUKEMIA Fathia El Riani, Rasem Al Ajnef, Elham Sbita, Salem Zarroug Departement of pediatric hematology-oncology.
Cancer of the blood: Leukemia
Myelodysplastic Syndrome (MDS)
Leukemia By: Gabie Gomez. What is Leukemia? Blood consists of plasma and three types of cells, each type has a special function. RBC, WBC and Platelets.
4th Year Medical Student KAU
Chronic myeloid leukaemia Cancer of granulocyte production Too many (non functioning) granulocytes are produced Bone marrow is overcrowded with ineffective.
Hematology and Hematologic Malignancies
Chronic leukemia 1. Chronic Lymphocytic leukemia (CLL) * Definition: Chronic neoplastic disorder characterized by accumulation of small mature-looking.
Chronic myeloid leukaemia (CML)
Leukemia Omidreza keshavarz Ahmad darvishi Nursing 86 Hormozgan university of medical sciences Bandarabbas faculty of nursing،midwifery and paramedical.
CHRONIC LEUKEMIA Dr. Hayam Hebah Associate professor of Internal Medicine AL Maarefa College.
Associate professor of Internal Medicine
Leukaemias. Leukaemias: Malignant Disease of WBC Forming tissue or other hemopoietic elements: Lymphoblastic (ALL) Lymphoblastic (ALL)Acute Myeloid (AML)
Acute myeloid leukemia
MLAB 1415: Hematology Keri Brophy-Martinez
MLAB Hematology Keri Brophy-Martinez
White blood cells and their disorders Dr K Hampton Haematologist Royal Hallamshire Hospital.
Hematopoetic Cancers. Hematopoesis Leukemia New diagnoses each year in the US: 40, 800 Adults 3,500 Children 21,840 died of leukemia in 2010.
Acute Leukemia Kristine Krafts, M.D..
By: Ashlynn Hill. Patrice Thompson  3 year who is battling leukemia.  The doctors suggest a bone marrow transplants for a long term survival.  Neither.
Treatment. Phases of treatment Induction chemotherapy Postremission therapy *Initial goal: quickly induce CR *Therapy depends on patient age.
Case report Sudden blastic transformation in patient with chronic myeloid leukemia treated with imatinib mesylate Mehrdad Payandeh,MD Hematology, Medical.
Leukemia. What is Leukemia?  Leukemia is a cancer of the blood  It is the most common type of blood cancer beginning in the bone marrow where abnormal.
Daunorubicin VS Mitoxantrone VS Idarubicin As Induction and Consolidation Chemotherapy for Adults with Acute Myeloid Leukemia : The EORTC and GIMEMA Groups.
LEUKEMIA Dr. Omar Alshaer. Acute Leukemia.
Acute lymphoblastic leukemia in children
AML Clinical Presentation. Clinical Presentation: Symptoms Fatigue (50%) Anorexia and weight loss Fever with or without an identifiable infection (10%)
Hematology There are four lectures: 1.Acute leukemias (2 hours). 2.Chronic leukemias (2 hours).
Acute leukemias.
Acute Leukemia Kristine Krafts, M.D..
Childhood leukemias Prof. Dr. P. Kajtár.
Acute myeloid leukemia
CLINICAL PROGRESSION INTRODUCTION METHOD CONCLUSION REFERENCES
Chronic Leukaemias Heterogeneous group of hematopoietic neoplasms
11 th lecture Chronic myeloid leukaemia By DR Fatehia Awny Faculty of Health Science Beirut Arab University
Asuhan Keperawatan Pasien Anak dengan Acut Lymphoblastic Leukemia
Chronic Leukaemias Heterogeneous group of hematopoietic neoplasms
CHRONIC MYELOID LEUKEMIA (CML)
Acute leukemia.
Diagnostic Hematology
Leukemia.
Acute Leukemia Dr. Noha Noufal.
Neoplastic disorder.
CHRONIC LEUKEMIA BY: DR. FATMA AL-QAHTANI CONSULTANT HAEMATOLOGIST
MYELOID LEUKEMIAS Dr. B.V.Vydehi M.D PROFESSOR OF PATHOLOGY
Presentation transcript:

Acute Leukemia Rakesh Biswas MD, Professor, Department of Medicine, People's College of Medical Sciences, Bhanpur, Bhopal, India

A 16 year old girl Extreme pallor gum bleeds, Purpura,With Lymphadenopathy and Hepatosplenomegaly

Possible causes: Investigations and treatment

Only a week later, D was ill again, with a fever, severe headache, and extreme lethargy.

During a sunny spring weekend, D would go outside to play, only to return minutes later exhausted, flopping herself onto the sofa to rest

Leukemia Group of malignant disorders of the hematopoietic tissues characteristically associated with increased numbers of white cells in the bone marrow and / or peripheral blood

Once inside the van and on our way out of the clinic parking lot, she asked, "Dad, what is leukemia?" "Can I die from this?"

Classification Classified based on cell type involved and the clinical course Classified based on cell type involved and the clinical course 1. Acute : 1. Acute : ALL ALL AML AML 2. Chronic : CLL CLL CML CML

Subclassification ALL ALL Common type( pre-B) Common type( pre-B) B-cell B-cell T-cell T-cell Undifferentiated Undifferentiated

After the oncologist performed a bone marrow aspiration to confirm the diagnosis of leukemia, we learned specifically what type it was and the count. "D had acute lymphoblastic leukemia, early pre-B cell.

Myelomono

AML French-American-British (FAB) Classification M0: Minimally differentiated leukemia M1: Myeloblastic leukemia without maturation M2: Myeloblastic leukemia with maturation M3: Hypergranular promyelocytic leukemia M4Eo: Variant: Increase in abnormal marrow eosinophils M4: Myelomonocytic leukemia M5: Monocytic leukemia M6: Erythroleukemia (DiGuglielmo's disease) M7: Megakaryoblastic leukemia Ref-Harrison’s Principle of Internal Medicine

CLL CLL B-cell: common B-cell: common T-cell: rare T-cell: rare

CML CML Ph +ve Ph +ve Ph –ve, BCR-abl +ve Ph –ve, BCR-abl +ve Ph –ve, BCR-abl -ve Ph –ve, BCR-abl -ve Eosinophilic Leukemia Eosinophilic Leukemia Ph: Philadelphia chromosome Ph: Philadelphia chromosome BCR: Breakpoint cluster region; abl : Abelson oncogene BCR: Breakpoint cluster region; abl : Abelson oncogene

Acute Myeloid Leukemia ( AML) Malignant transformation of a myeloid precursor cell ; usually occurs at a very early stage of myeloid development Malignant transformation of a myeloid precursor cell ; usually occurs at a very early stage of myeloid development Rare in childhood & incidence increases with age Rare in childhood & incidence increases with age

Etiology Unknown / De-novo !! In majority Predisposing factors: Ionizing radiation exposure Ionizing radiation exposure Previous chemotherapy : alkylating agents Previous chemotherapy : alkylating agents Occupational chemical exposure : benzene Occupational chemical exposure : benzene Genetic factors: Down’s Syndrome, Bloom’s, Fanconi’s Anemia Genetic factors: Down’s Syndrome, Bloom’s, Fanconi’s Anemia Viral infection ( HTLV-1) Viral infection ( HTLV-1) Immunological : hypogammaglobulinemia Immunological : hypogammaglobulinemia Acquired hematological condition -Secondary Acquired hematological condition -Secondary

Epidemiology M > F M > F ALL which predominantly affects younger individuals ALL which predominantly affects younger individuals AML – adults and the elderly AML – adults and the elderly Median age gp-65yrs Median age gp-65yrs Geographical variation-none Geographical variation-none

Clinical features General : Onset is abrupt & stormy General : Onset is abrupt & stormy (usually present within 3 months) (usually present within 3 months) Bone marrow failure (anemia, infection,bleeding) Bone marrow failure (anemia, infection,bleeding) Bone pain & tenderness Bone pain & tenderness

Specific: M2 : Chloroma:-presents as a mass lesion ‘tumor of leukemic cells’ M2 : Chloroma:-presents as a mass lesion ‘tumor of leukemic cells’ M3 : DIC M3 : DIC M4/M5 : Infiltration of soft tissues, gum infiltration, skin deposits,Meningeal involvement-headache, vomiting, eye symptoms M4/M5 : Infiltration of soft tissues, gum infiltration, skin deposits,Meningeal involvement-headache, vomiting, eye symptoms

Skin Infiltration with AML (Leukemia Cutis)

Diagnosis Blood count : WBC usually elevated (50,000- 1,00,000 / cmm ); may be normal or low; often anemia & thrombocytopenia Blood count : WBC usually elevated (50,000- 1,00,000 / cmm ); may be normal or low; often anemia & thrombocytopenia Blood film : (as above) Blast cells Blood film : (as above) Blast cells

P. Smear AML

Bone marrow aspirate & trephine: Hypercellular, Bone marrow aspirate & trephine: Hypercellular, blast cells ( > 20%), blast cells ( > 20%), presence of Auer rods - AML type presence of Auer rods - AML type Cytochemistry : Special stains to differentiate AML from ALL ; Positivity with Sudan black & Myeloperoxidase (MPO) in AML Cytochemistry : Special stains to differentiate AML from ALL ; Positivity with Sudan black & Myeloperoxidase (MPO) in AML

Jemshidi trephine & Salah aspiration needle

Auer Rods in Leukemia cells

MPO (right) & Sudan black (left) showing intense localised positivity in blasts

Confirmation: Confirmation: Immunophenotyping Immunophenotyping Molecular genetics Molecular genetics Cytogenetics: Chromosomal abnormalities Cytogenetics: Chromosomal abnormalities

Other Inv : Coagulation screen, fibrinogen, D- dimer Coagulation screen, fibrinogen, D- dimer RFT, LFT RFT, LFT LDH, Uric acid LDH, Uric acid Urine Urine CXR CXR ECG, ECHO ECG, ECHO

Management I. Supportive care : I. Supportive care : Anemia – red cell transfusion Anemia – red cell transfusion Thrombocytopenia – platelet concentrates Thrombocytopenia – platelet concentrates Infection – broad spectrum IV antibiotics Infection – broad spectrum IV antibiotics Hematopoietic growth factors : GM-CSF, G-CSF Hematopoietic growth factors : GM-CSF, G-CSF Barrier nursing Barrier nursing Indwelling central venous catheter Indwelling central venous catheter

Metabolic problems : Monitoring hepatic / renal / hematologic function; Fluid & electrolyte balance, nutrition Hyperuricemia- hydration, Allopurinol Metabolic problems : Monitoring hepatic / renal / hematologic function; Fluid & electrolyte balance, nutrition Hyperuricemia- hydration, Allopurinol Psychological support Psychological support

The white blood cell count in her peripheral blood was about 550,000. Her bone marrow was packed with leukemia blasts."

The next thing that occurred was a procedure called leukopheresis. This procedure lasted 4 hours and cut D’s white blood cell (WBC) count in half--to about 250,000.

She was administered chemotherapy immediately following the leukopheresis procedure. The next day we learned that the chemo had produced an effect as well: The WBC had halved again--125,000.

SPECIFIC THERAPHY: Chemotherapy : Induction: (4-6 wks) vincristine, prednisone, anthracycline, (idarubicin or daunorubicin) cyclophosphamide, and L-asparaginase

Consolidation: (multiple cycles of intensive chemotherapy given over a 6 to 9 month period). Cytosine arabinoside, high-dose methotrexate, etoposide anthracycline, (idarubicin or daunorubicin)

Maintenance phase: (18 to 24 months). LPs with intrathecal MTX every 3 months, Monthly vincristine, Daily 6-MP, and weekly MTX.

At day 29 of the induction protocol D was declared to be in complete remission. We were all relieved with this news.

Step two was the next phase of treatment called consolidation therapy. This entailed multiple combinations of drugs administered on a rotational basis (on various weeks) for the next six months.

For instance, she would receive an infusion of methotrexate for a couple of days and then take 6- MP by mouth for a week. Another cycle included VM-26 (Teniposide) and Ara-C.

Complete remission ( CR): < 5% blast cells in normocellular bone marrow Complete remission ( CR): < 5% blast cells in normocellular bone marrow Autologous BMT : Can be curative in younger patient (< yrs) Autologous BMT : Can be curative in younger patient (< yrs)

Exactly 5 months since her diagnosis, and 16 weeks of remission… "We're at the clinic. D has relapsed. Her white count is 27,000."

The Consolidation protocol had been dropped and replaced with a new induction protocol. After the bone marrow aspiration to determine the extent of the leukemia relapse, she was given doxirubicin, vincristine and L-asparaginase.

For several days following D‘s discharge from the bone marrow transplant unit, all of us loaf around the house and recuperate from our 90 day marathon…

…the first 30 days representing Ds' relapse and the induction therapy to obtain a second remission

Back in fighting form, D proceeds directly to the final 30 days of the marathon--the actual bone marrow transplant. BMT patients are in a delicate condition following discharge

Looking back, the nine weeks or so--the post BMT discharge period--was a sublime time for us. D was home and was feeling pretty good.

As D’s hair began to grow again, we rubbed her head every night at the dinner table, wondering what color it was going to be or if it was going to be curly or straight. We never found out.

On Monday, March 1, 1999 we went to clinic and waited for the lab results. The results came back as we feared. D had relapsed. Her white count was 47,000. We were devastated.

III. PALLIATIVE THERAPHY III. PALLIATIVE THERAPHY Chemo, RT, Blood product support Chemo, RT, Blood product support

Prognosis Median survival without treatment is 5 weeks Median survival without treatment is 5 weeks 30% 5-yr survival in younger patients with chemotherapy 30% 5-yr survival in younger patients with chemotherapy Disease which relapses during treatment or soon after the end of treatment has a poor prognosis Disease which relapses during treatment or soon after the end of treatment has a poor prognosis

Poor prognostic factors Increasing age Increasing age Male sex Male sex High WBC count at diagnosis High WBC count at diagnosis CNS involvement at diagnosis CNS involvement at diagnosis Cytogenetic abnormalities Cytogenetic abnormalities Antecedent hematological abnormalities (eg. MDS) Antecedent hematological abnormalities (eg. MDS) No complete remission No complete remission

Two things that I will always remember about D: She was a collector of many things, trinket boxes, key rings. But she was first and foremost a collector of "FRIENDS."

Among other things, she wrote: "Hair loss is a side effect of chemotherapy, and cancer is a side effect of life."

Summary; Learning Points

THANK YOU THANK YOU